[Study on relativity between oxygen free radical and thromboxane B2, 6-keto-PGF1 alpha during ligustrazine treatment of intrauterine growth retardation].
OBJECTIVE
To study the pathophysiological changes and effective treatment of intrauterine growth retardation (IUGR).


METHODS
Eighty-five cases with normal pregnancy and 58 IUGR women maternal red blood cell superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), serum lipid peroxide (LPO) and thromboxane B2 (TXB2), 6-keto-PGF1 alpha(6KP) were examined. IUGR group was divided into Ligustrazine group (LIG, 47 cases) and amino acid group (AAG, 11 cases) and treated accordingly.


RESULTS
In IUGR group, LPO increased and SOD, GSH-Px activity, 6KP value decreased abnormally, TXB2/6KP ratio significantly increased, which was negative correlated with SOD, GSH-Px activity and positive correlated with LPO level markedly. After treatment, all the changes were improved and almost reached normal range. The fetal outcome showed that the total effective rate was 95.7% in LIG, markedly higher than that in AAG (81.8%, P < 0.05), there was significant difference between LIG and AAG.


CONCLUSIONS
The balance of body oxidate/antioxidate system was disturbed and the uteroplacental-fetal circulation was obstracted in IUGR. Ligustrazine could inhibit oxygen free radical, rise SOD, GSH-Px activity, regulate TXA2/PGI2 balance, promote fetal growth.
Xu
J
J
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical University, Wuhan 430030.
Ma
T
T
Wen
L
L
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000328:Adult; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy*; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006801:Humans; D011247:Pregnancy; D011719:Pyrazines / Q000627:therapeutic use*; D013482:Superoxide Dismutase / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood*
D016166:Free Radical Scavengers; D011719:Pyrazines; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D013482:Superoxide Dismutase; C017953:tetramethylpyrazine